The final, formatted version of the article will be published soon.
REVIEW article
Front. Med.
Sec. Nephrology
Volume 12 - 2025 |
doi: 10.3389/fmed.2025.1500166
Progress in the Application of Novel Inflammatory Indicators in Chronic Kidney Disease
Provisionally accepted- 1 China Three Gorges University, Hubei, China
- 2 Gezhouba Central Hospital of Sinopharm, Yichang, Hubei Province, China
Chronic kidney disease has become a public health problem endangering the health of all humans because of its high prevalence, high mortality and high medical burden. The chronic micro-inflammatory state is recognized as a significant component of CKD, playing a key role in disease progression. Intervening in chronic inflammation during the disease course can enhance prognosis. Recent studies have demonstrated that novel inflammatory indices, such as the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammatory index are closely associated with CKD, meanwhile may serve as prognostic monitors of all-cause death and poor renal prognosis for the disease. This article comprehensively reports on the mechanisms of micro-inflammation in CKD, the relationship between inflammatory indicators and CKD, and their impact on prognosis.
Keywords: Chronic Kidney Disease, Micro-inflammation, Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, relationship, prognosis
Received: 22 Sep 2024; Accepted: 14 Jan 2025.
Copyright: © 2025 Gao, Wang, Zou, Wang, Dou and Qian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiangyu Wang, Gezhouba Central Hospital of Sinopharm, Yichang, Hubei Province, China
Yulin Zou, Gezhouba Central Hospital of Sinopharm, Yichang, Hubei Province, China
Jun Dou, Gezhouba Central Hospital of Sinopharm, Yichang, Hubei Province, China
Senlin Qian, Gezhouba Central Hospital of Sinopharm, Yichang, Hubei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.